Your browser doesn't support javascript.
loading
Scandiatransplant acceptable mismatch program (STAMP) a bridge to transplanting highly immunized patients.
Koefoed-Nielsen, P; Weinreich, I; Bengtsson, M; Lauronen, J; Naper, C; Gäbel, M; Sørensen, S S; Wennberg, L; Reisaeter, A V; Møller, B K.
Afiliación
  • Koefoed-Nielsen P; Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
  • Weinreich I; Scandiatransplant office, Aarhus, Denmark.
  • Bengtsson M; Department of Clinical Immunology, Rudbeck Laboratory, Uppsala University Hospital, Uppsala, Sweden.
  • Lauronen J; Finnish Red Cross Blood Service, Helsinki, Finland.
  • Naper C; Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway.
  • Gäbel M; Sahlgrenska University Hospital, Institute of Transplantation, Gothenburg, Sweden.
  • Sørensen SS; Department of Nephrology, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark.
  • Wennberg L; Department of Transplantation Surgery, Karolinska University Hospital, Stockholm, Sweden.
  • Reisaeter AV; Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Møller BK; Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
HLA ; 90(1): 17-24, 2017 07.
Article en En | MEDLINE | ID: mdl-28449350
BACKGROUND: Highly immunized patients are a challenge for organ transplantation programs. One way of increasing the likelihood of transplantation in this group of patients is to expand the possible donations by defining acceptable HLA mismatches. In the Scandiatransplant Acceptable Mismatch Program (STAMP), a de-centralized approach has been implemented in 2009. AIMS: The program has been improved during the years from utilizing HLA-A, -B, -DR matching only to include typing of all deceased donors for HLA-A, -B, -C, -DRB1 and -DQB1. The calculation of a transplantability score (TS) has been introduced in order to take both HLA and AB0 into consideration resulting in a more realistic picture of the transplantability chance. MATERIALS AND METHODS: Patients were selected for eligibility and results of immunisation status were prepared in each of the 9 tissue typing laboratories, while access to the program is finally governed by a common steering group of immunologists and clinicians. RESULTS: In the period from March 2009 until February 2015, 96 patients were transplanted within this program. The mean recipient age was 49 years and 57% were females, 30% of the patients were first transplants and of these 93% were females. The majority of the patients had 2-5 HLA-A, -B. -DR mismatches. The allograft survival at 60 months was 79.1%. Applying the TS to the cohort confirmed that patients with a low TS score had longer waiting times. CONCLUSION: The program has matured during the years and now proves to be a valid approach for transplanting highly immunized patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Donantes de Tejidos / Obtención de Tejidos y Órganos / Trasplante de Riñón / Receptores de Trasplantes / Rechazo de Injerto / Antígenos HLA Límite: Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: HLA Año: 2017 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Donantes de Tejidos / Obtención de Tejidos y Órganos / Trasplante de Riñón / Receptores de Trasplantes / Rechazo de Injerto / Antígenos HLA Límite: Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: HLA Año: 2017 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Reino Unido